Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million for the quarter, compared to analysts ...

The business has a fifty day moving average of $6.81 and a 200 day moving average of $7.14. Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its quarterly earnings ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma ...

Recursion Pharmaceuticals (RXRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Alec Stranahan from Bank of America Securities ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Recursion Pharmaceuticals. Looking at options history for Recursion Pharmaceuticals RXRX we detected 8 trades.

See the 10 stocks » Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotech that may have that level of potential. The company harnesses artificial intelligence (AI) for drug ...

Recursion Pharmaceuticals ... Legal counsel Wilson Sonsini Goodrich & Rosati, P.C. has provided an opinion on the legality of the Resale Shares, which is included in the SEC filing as Exhibit ...

Then eventually that royalty stack starts to add up and it's cutting into your profitability long term.” In the companies’ “Learnings call” explaining the merger, Recursion CEO Chris ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report). The company’s shares closed yesterday at $7.46.

In this article, we are going to take a look at where Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stands against other stocks highlighted in Jim Cramer's latest calls. Jim Cramer in a recent ...